-
Je něco špatně v tomto záznamu ?
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
S. Borchmann, H. Müller, H. Haverkamp, C. Baues, J. Marková, A. Hüttmann, A. Glunz, M. Fuchs, P. Borchmann, A. Engert,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- dospělí MeSH
- Hodgkinova nemoc komplikace MeSH
- kombinovaná terapie škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mladiství MeSH
- mladý dospělý MeSH
- následné studie MeSH
- osteonekróza etiologie prevence a kontrola MeSH
- prognóza MeSH
- prospektivní studie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
The majority of patients with Hodgkin Lymphoma (HL) can be cured with stage and risk adapted treatment today. Therefore, current research focuses on reducing long-term sequelae of treatment. Osteonecrosis (ON) is a severe long-term complication of HL treatment which has so far not been systematically evaluated. Hence, we investigated incidence, risk factors and timing of symptomatic ON in HL patients. Further endpoints included localization, intervention and outcome of ON. We included all qualified HL patients of the randomized German Hodgkin Study Group trials HD10-15 and HD18, recruited between 05/1998 and 07/2014 and aged from 16 to 60 years. Among 11 330 patients, 66 developed symptomatic ON after first-line treatment, 83.3% within three years. The incidence of symptomatic ON was 0.2% in early-stage HL and 1.0% in advanced-stage HL. Logistic regression revealed the total cumulative corticosteroid dose to be a strong risk factor interacting with younger age. Male sex additionally increased the risk of symptomatic ON. The prognostic value of the corresponding logistic regression model was rather high (AUC = 0.78). Other tested potential risk factors including obesity, IPS and radiotherapy did not further increase the risk of ON. Further development of current treatment protocols should aim to reduce the cumulative corticosteroid dose.
Department of Haematology University Hospital University Duisburg Essen Duisburg Germany
Department of Radio Oncology University Hospital of Cologne Cologne Germany
Institute of Medical Statistics and Computational Biology University of Cologne Cologne Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028258
- 003
- CZ-PrNML
- 005
- 20190815105430.0
- 007
- ta
- 008
- 190813s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-018-0240-8 $2 doi
- 035 __
- $a (PubMed)30131583
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Borchmann, Sven $u Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany.
- 245 10
- $a Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG) / $c S. Borchmann, H. Müller, H. Haverkamp, C. Baues, J. Marková, A. Hüttmann, A. Glunz, M. Fuchs, P. Borchmann, A. Engert,
- 520 9_
- $a The majority of patients with Hodgkin Lymphoma (HL) can be cured with stage and risk adapted treatment today. Therefore, current research focuses on reducing long-term sequelae of treatment. Osteonecrosis (ON) is a severe long-term complication of HL treatment which has so far not been systematically evaluated. Hence, we investigated incidence, risk factors and timing of symptomatic ON in HL patients. Further endpoints included localization, intervention and outcome of ON. We included all qualified HL patients of the randomized German Hodgkin Study Group trials HD10-15 and HD18, recruited between 05/1998 and 07/2014 and aged from 16 to 60 years. Among 11 330 patients, 66 developed symptomatic ON after first-line treatment, 83.3% within three years. The incidence of symptomatic ON was 0.2% in early-stage HL and 1.0% in advanced-stage HL. Logistic regression revealed the total cumulative corticosteroid dose to be a strong risk factor interacting with younger age. Male sex additionally increased the risk of symptomatic ON. The prognostic value of the corresponding logistic regression model was rather high (AUC = 0.78). Other tested potential risk factors including obesity, IPS and radiotherapy did not further increase the risk of ON. Further development of current treatment protocols should aim to reduce the cumulative corticosteroid dose.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a kombinovaná terapie $x škodlivé účinky $7 D003131
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a Hodgkinova nemoc $x komplikace $7 D006689
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a osteonekróza $x etiologie $x prevence a kontrola $7 D010020
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Müller, Horst $u Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Haverkamp, Heinz $u Institute of Medical Statistics and Computational Biology, University of Cologne, Cologne, Germany.
- 700 1_
- $a Baues, Christian $u Department of Radio-Oncology, University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Marková, Jana $u Department for Internal Medicine and Hematology, University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Hüttmann, Andreas $u Department of Haematology, University Hospital, University Duisburg-Essen, Duisburg, Germany.
- 700 1_
- $a Glunz, Axel $u Department of Haematology, University Hospital, University Duisburg-Essen, Duisburg, Germany.
- 700 1_
- $a Fuchs, Michael $u Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Borchmann, Peter $u Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Engert, Andreas $u Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany. a.engert@uni-koeln.de.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 33, č. 2 (2019), s. 439-446
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30131583 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190815105657 $b ABA008
- 999 __
- $a ok $b bmc $g 1433407 $s 1066718
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 33 $c 2 $d 439-446 $e 20180821 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20190813
